Primary Lymphedema and Mutation CELSR1 (Cadherin EGF LAG Seven-pass G-type Receptor 1)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

31 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2022-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will describe the expression of mutation CELSR1 with codon stop and amino acids substitution mechanism in primary lymphedema, in both clinical examination and imaging exploration

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France

NCT02887781

Tuberous Sclerosis Complex

RECRUITING

Lymphangioleiomyomatosis, a Study on Cathepsin K

NCT05323370

Lymphangioleiomyomatosis Tuberous Sclerosis Complex

COMPLETED

Cohort Follow-up of Patients With Renal or Craniocervical Fibromuscular Dysplasia

NCT02961868

Fibromuscular Dysplasia

COMPLETED NA

Prediction of Recruitment Potential of Participating Centers in Clinical Trials by Standardized Translation of Selection Criteria and Queries From DRG Database

NCT03019068

Multicenter Clinical Study

WITHDRAWN

NIPD on cffDNA for Triplet Repeat Diseases

NCT04698551

Myotonic Dystrophy 1 Huntington Disease Fragile X Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to the literature, it seems that the mutation of the CELSR1 gene is associated with primary lymphedema.

Thus, the investigators have identified families with CELSR1 mutation with codon stop or animo acid substitution mechanisms among patients followed up in vascular medicine department, at Montpellier University hospital for primary lymphedema of lower limbs.

Among the mutation carriers, the investigators have collected the clinical examinations and imaging exploration results, realized systematically during the follow up of all the patient with primary lymphedema (venous Doppler, MRI of the lymphatic system, lymphoscintigraphy of the lower limbs, abdominal ultrasound), in order to search for a morphological and functional pattern associated with the mutation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient followed up in vascular medicine departement at Montpellier University Hospital for primary lymphedema of lower limbs, who carries the CELSR1 mutation with codon stop or amino acids substitution mechanism.
* Relatives to the index case who carry the mutation for the segregation study.

Exclusion Criteria

* Patients who carry another mutation than CELSR1 responsible for primary lymphedema
* Syndromic form of primary lymphedema
* Patient not followed up at Montpellier University Hospital.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes